Hepmend Sachet contains L-Ornithine L-Aspartate (3 gm), an amino acid compound used primarily in the management of hepatic encephalopathy and other liver-related disorders. This formulation acts by promoting the detoxification of ammonia, a neurotoxic substance that accumulates in patients with impaired liver function. L-Ornithine L-Aspartate facilitates the conversion of ammonia into urea and glutamine, thereby reducing hyperammonemia and improving neurological symptoms associated with hepatic insufficiency. Hepmend is indicated as an adjunctive therapy in chronic liver diseases, including cirrhosis and acute liver failure, where elevated blood ammonia levels contribute to cognitive dysfunction. The sachet form allows for convenient oral administration, ensuring rapid absorption and onset of action. Clinical studies have demonstrated that L-Ornithine L-Aspartate effectively lowers blood ammonia concentrations and enhances patient quality of life by alleviating symptoms such as confusion, lethargy, and disorientation. Hepmend is generally well tolerated, with minimal adverse effects reported. It should be used under medical supervision, particularly in patients with severe hepatic impairment or concomitant illnesses. Dosage and duration of therapy must be individualized based on clinical response and laboratory parameters to optimize therapeutic outcomes.